Cipla

12th February 2015

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

This is to inform you that the Company has signed a definitive agreement to acquire 60% stake of Jay Precision Pharmaceuticals Private Limited ("Jay Precision"), Mumbai, from the existing shareholders, for a cash consideration of Rs. 96 crore.

Jay Precision is an existing supplier of respiratory devices to the Company and has a state of the art manufacturing facility at Vasai, Maharashtra. Considering Company's leading position in inhalation therapy, this transaction is aimed at integrating the value chain and will serve as platform for development of next generation respiratory devices.

Pharmaceutical undertaking of Jay Precision Products (India) Private Limited was demerged into Jay Precision effective 1st January 2014. Turnover of Jay Precision for the year ended 31st March 2014 was Rs.30 crores.

The transaction is expected to be completed by end of this financial year, subject to completion of certain conditions precedent.

None of the persons belonging to Promoter / Promoter Group(s) of the Company has any interest in the transaction and it is not a related party transaction for the Company. The transaction does not require any governmental or regulatory approval(s).

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary